Significance of TP53 mutations as predictive markers of adjuvant cisplatin‐based chemotherapy in completely resected non‐small‐cell lung cancer

Adjuvant cisplatin‐based chemotherapy only marginally improves survival in patients with completely resected non‐small‐cell lung cancer (NSCLC). We have evaluated the predictive value of mutations in TP53, encoding the tumour suppressor p53, in the International Adjuvant Lung Cancer Trial (IALT), a...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Mol Oncol
Главные авторы: Ma, Xiaoli, Rousseau, Vanessa, Sun, Haiji, Lantuejoul, Sylvie, Filipits, Martin, Pirker, Robert, Popper, Helmut, Mendiboure, Jean, Vataire, Anne-Lise, Le Chevalier, Thierry, Soria, Jean Charles, Brambilla, Elisabeth, Dunant, Ariane, Hainaut, Pierre
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2014
Предметы:
Research Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528648/
https://ncbi.nlm.nih.gov/pubmed/24495481
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2013.12.015
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы